Drug intelligence / Profile preview

Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)

Development stage
Approved
Lead developer
Sanofi
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) is a toxoid vaccine component used for active immunization against diphtheria, a serious infectious disease caused by the bacterium *Corynebacterium diphtheriae*. The diphtheria toxin, which is responsible for the severe symptoms of the disease, is purified from the bacteria and then inactivated with formaldehyde. This chemical treatment renders the toxin non-toxic while preserving its antigenic properties. When administered, this inactivated toxoid stimulates the immune system to produce specific antibodies and antitoxins. These antibodies can then neutralize the actual diphtheria toxin if an individual is exposed to the bacterium, thereby preventing the development of diphtheria. It is a widely used and effective component in various combination vaccines, such as DTaP, Tdap, DTP, and DT, which protect against diphtheria, tetanus, and often pertussis.

Brand names
TDVAXTENIVACDaptacelInfanrixAdacelBoostrixPediarixPentacelVaxelisQuadracel
Other names
Diphtheria toxoid
02

Targets

Diphtheria toxin

Beyond the preview

Go deeper on Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call